Three new Hep C treatments on the PBAC agenda for March

On Christmas Eve the Pharmaceutical Benefits Advisory Council released its agenda for the March 2015 meeting. Among the list of medicines to be considered for listing on the PBS are four treatments for hepatitis C. These include: 

  • asunaprevir (BMS) for the treatment of chronic genotype 1b hepatitis C;
  • daclatsavir (BMS) for the treatment of hepatitis C;
  • ledipasvir + sofosbuvir (Gilead) for the treatment of chronic hepatitis C, genotype 1; and
  • sofosbuvir (Gilead) for treatment of hepatitis C (this was previously rejected by PBAC)

In addition, Ribavirin (Clinect) is on the agenda for the treatment of hepatitis C
genotypes 2 and 3 in combination with sofosbuvir)

PBAC is again seeking submissions from the community to inform their discussions and recommendations.  You can find out more about lodging a submission here

Submissions close on the 11th February 2015

If you require any support in preparing a submission you can contact your local hepatitis organisation by calling 1300 437 222 after the 5th January 2015.